| 摘要: |
| 非小细胞肺癌（non-small cell lung cancer, NSCLC）占肺癌发病率的80%～85%。由于缺乏早期诊断的特异性生物标志物及方法，多数患者确诊时已为晚期。目前手术、放化疗和靶向治疗等是治疗NSCLC的主要手段。近年来，对miRNA的深入研究表明，miRNAs的异常表达与NSCLC发生、发展密切相关。循环miRNA的发现，为NSCLC的早期诊断和个体化治疗提供了一种潜在的生物学标志物和治疗手段。本文主要就近年来miRNAs在NSCLC中的调控机制及在诊断和治疗中的研究进展进行综述。 |
| 关键词: 非小细胞肺癌 miRNAs 生物学标志物 早期诊断 |
| DOI：10.11724/jdmu.2017.01.19 |
| 分类号:R734.2 |
| 基金项目:基金项目：辽宁省自然科学基金项目（2013023003） |
|
| Dysregulation of miRNAs in NSCLC and their application in diagnosis and treatment |
|
LI Rui-hua1, LIU Bo2, WU Yingjie2
|
|
1.Department of Clinical Laboratory, the Second Affiliated Hospital of Dalian Medical University, Dalian 116027, China;2.Institute of Genome Engineered Animal Models for Human Disease, Dalian Medical University, Dalian 116044, China
|
| Abstract: |
| Lung cancer is the most common malignance and the leading cause of cancer mortality worldwide. Non-small cell lung cancer (NSCLC) accounts nearly 80%-85% of the lung cancer. Due to the lack of specific biomarkers and tools for early diagnosis, most of the NSCLC patients are diagnosed at advanced stage. Surgical resection, radio- and chemo-therapies，and targeted therapy are the main treatments for NSCLC. In recent years, studies of microRNAs (miRNAs) have indicated that the aberrant expression of miRNAs is closely related to the development and progression of NSCLC. The detection of circulating miRNA provides potential biomarkers and tools for early diagnosis and individualized treatment. In this paper, the research of miRNAs in diagnosis and therapies of NSCLC are reviewed. |
| Key words: NSCLC miRNAs biomarkers early diagnosis |
